Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Opioid Analgesics Market Outlook (2023 to 2033)

According to a recent assessment by Future Market Insights (FMI), the opioid analgesics market is slated to expand at a 5.2% CAGR, attaining US$ 43.3 billion in 2023. Soaring demand for post-surgery pain management and advancements in drug formulations to reduce analgesic side effects are predicted to propel sales of opioid analgesics over the forecast period.

Morphin sales are expected to command 13% of the overall opioid analgesics market share, with a market valuation of US$ 72.0 billion by 2033, according to FMI.

The Opioid Analgesics Key Determinants - Creating Hype

Opioid analgesics are ideal for pain management and palliative care due to their convenience and efficacy. However, to reduce the risk of addiction and overuse, definite restrictions on opioid sales are in place.

As a result, manufacturers are trying to enhance their product offerings by investing in research and development to develop milder and less addictive drugs. It points to lucrative market growth opportunities for key opioid analgesics manufacturers.

The Valuable Opportunities for Market Makers in the Couple of Years

On the other hand, many people believe that smaller doses of opioids are ineffective in alleviating severe pain. These patients require more drugs to relieve their pain, which inevitably leads to opioid tolerance and, in some cases, addiction to these drugs.

One of the primary opportunities for opioid analgesic manufacturers in the opioid drugs market is expected to be the commercialization of opioid-tolerant drugs. It helps to reduce the side effects caused by or associated with high opioid drug consumption, which is estimated to boost sales of opioid analgesics in the coming years.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

The Opioid Analgesics Market's Hurdles

The Rising Prevalence of Opioid Addiction May Harm its Sales

The primary factors limiting global market growth are the unavailability of opioids in emerging markets and the side effects associated with these drugs. Aside from that, the escalating magnitude of abusive opioids and their misuse impedes global market growth.

Furthermore, chronic opioid side effects pose a significant barrier to market growth. Due to the increased abuse of addictive opioids, physicians have scaled back their pain management prescriptions, decreasing global sales. The rising prevalence of opioid abuse is expected to stifle market growth, as practitioners are hesitant to prescribe opioids as pain relievers.

Attributes Details
Market CAGR (2023 to 2033) 5.2%
Market Valuation (2023) US$ 43.3 billion
Market Valuation (2033) US$ 72.0 billion

Opioid Analgesics Market by Drug Class

According to the drug class, oxycodone is expected to account for 19.1% of the global market. Oxycodone is one of the most potent pain relievers on the market. The medication relieves pain and allows patients to go about their daily activities.

Previously, oxycodone was not widely used due to a lack of knowledge about the constituents and the high cost of drugs. The rising awareness about the benefits of oxycodone, such as increased bioavailability, is encouraging the drug's use.

Global Market by Indication

Due to the rise in surgical procedures and the incidence of associated post-operative pain, the indication of surgical pain is expected to account for 45.9% of the opioid analgesics market share.

Opioid analgesics are used as an effective treatment for pain management following an operation or surgery. Over the forecast period, increased adoption of medications for pain management and relief is expected to drive demand for opioid analgesics.

Global Market by Route of Administration

Hospital pharmacies are expected to account for 33.4% of the total market share. Hospitals are leading care facilities with a large presence of well-trained staff and professionals who assist patients in receiving effective treatment. Adoption of prescribed therapy in clinics and hospitals aids in physician-supervised drug delivery. It is one of the primary factors driving sales of opioid analgesics through hospital pharmacies.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Countries of High Interest in the Opioid Analgesics Market

Countries Forecast Share Between 2023 to 2033
United States 41.9%
Germany 5.7%
Japan 4.2%
Countries Forecast CAGR Between 2023 to 2033
Australia 4%
China 7.7%
India 5.3%
United Kingdom 4.3%

The United States is an Enticing Market for Opioid Analgesics

The United States is expected to dominate the global market, accounting for 41.9% of the global market. The rising prevalence of chronic illnesses, as well as the growing adoption of opioid analgesics as pain relievers, is expected to continue to boost sales of opioid analgesics.

Key opioid analgesic manufacturers in the United States are focusing on launching new products to comply with updated regulatory procedures. Furthermore, government-led investments in clinical research are estimated to enable the country to maintain its dominance over the forecast period.

Demand Perspective for Opioid Analgesics in Germany

In Germany, sales of opioid analgesics are expected to record a 3.8% CAGR, reaching a valuation of US$ 2.2 billion in 2023. Germany is estimated to secure a CAGR of 5.7% in the global market by 2033.

Adoption of opioid maintenance treatment (OMT) for treating opioid dependence (O.D.), increased use of non-abusive opioids, and favorable reimbursement programs offered by German regulatory bodies regarding awareness of palliative care are key factors driving sales of opioid analgesics in Germany.

Maddening Buzz about Opioid Analgesics Recorded in the United Kingdom

The United Kingdom is expected to lead the European market, with sales increasing at a 4.3% CAGR during the forecast period.

The healthcare system in the United Kingdom is well-known and universal, with significant government funding. It is widely regarded as having one of the most thriving healthcare systems in the world.

The United Kingdom is the third leading global market, and this position is expected to be maintained throughout the forecast period. Furthermore, the presence of several key players, expanding pipeline drugs, and increasing research efforts create lucrative global market opportunities in the United Kingdom.

China Perceived as an Emerging Country for Opioid Analgesics

China is expected to lead the East Asian market in 2023, accounting for a CAGR of 7.7% in the global market share. Due to the increasing use of large amounts of opioids for pain management and its extensive manufacturing capacity, China dominates the East Asian market.

Due to rapid productivity and large-scale capital investments in the healthcare sector, China is the world's second-largest pharmaceutical market.

Increasing Sales of Opioid Analgesics in India May Drive Market Growth

India is anticipated to account for 35.4% of the South Asian market for opioid analgesics, with sales increasing at a steady 5.3% CAGR.

Due to the nation's rising need for opioid analgesics, small and large pharmaceutical companies in India actively fund research and development. Many innovative drugs in the funnel are mostly finished and are estimated to be accessible to patients soon.

Clinical trials for opioid analgesics are made possible by government-funded healthcare and pharmaceutical institutions in India. In the upcoming years, the increase in research activities underway in India is anticipated to fuel the global market.

Startup Ecosystem in the Global Market

  • Novaremed

With the addition of two complementary development initiatives, the acquisition of Metys expands Novaremed's pipeline of novel, non-opioid development candidates for chronic pain indications.

With the addition of chemotherapy-induced peripheral neuropathy (CIPN) to its current focus on excruciating diabetic peripheral neuropathy, Novaremed's pipeline expansion enables it to target a wider segment of neuropathic pain indications (PDPN).

  • Pharmachal

The company announced that Bristol Myers Squibb acquired Turning Point Therapeutics, Inc. in an all-cash deal. Turning Point is now a fully owned subsidiary of Bristol Myers Squibb after the acquisition was finalized, and shares of Turning Point no longer trade on the NASDAQ Global Select Market.

  • AntalGenics

AntalGenics, a Spanish startup, created novel molecules to treat chronic pain. The startup is looking into two molecules, AG1529 and AG1531, to treat osteoarthritis pain and psoriatic pruritus. Additionally, the startup creates cosmetic active ingredients for skin and scalp sensitivity.

At in-cosmetics Virtual 2020, AntalGenics is estimated to introduce two of its cutting-edge neuro cosmetic ingredients: Capsisilence, which promotes a healthy scalp, and Calmapsin, which lessens the signs of sensitive skin.

  • InnoPain

A drug to mimic the effects of morphine without the negative side effects is being developed by the French startup InnoPain. The analgesic effect of morphine is produced by an interaction between the startup's lead candidate, TREK-1, and the -opioid receptor (OR). The startup is also working on RNE28, a new oral and intravenous analgesic medication class.

  • Neumentum

The pharmaceutical company Neumentum has raised US$ 6 million in a Series A funding round by selling Series A Convertible Preferred Stock. Momentum is committed to revolutionizing how acute and chronic pain is treated without using opioids. The sole placement agent for the financing was Brookline Capital Markets.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Competitve Landscape

Crucial players emphasize product portfolio expansion by launching new and updated products in the emerging market. Players in the market for opioid analgesics are anticipated to benefit from product approvals, agreements, partnerships, facility expansion, and strategic collaborations to achieve a competitive advantage.

Pfizer Inc., Abbott Laboratories, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Bayer AG, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Bausch Health Companies Inc., and Sanofi S.A. are some of the significant players operating in the market for opioid analgesics.

Recent Developments in the Global Market are:

The FDA approved the new drug application Allergan PLC submitted in January 2020. The application was made by a business called DURYSTA for the Food and Drug Administration. It is the first of its kind and aims to lower intraocular pressure by giving sustained-release, biodegradable medication. Due to open-angle glaucoma and ocular hypertension (OHT), this is possible.

The FDA disclosed that the Prescription Drug User Fee Act (PDUFA) may come into effect on December 1st, 2019, at Veritas Pharma Inc. In 2020, Daiichi Sankyo declared its plan to collaborate with Ultragenyx Pharmaceutical to enhance research.

Scope of Report

Attributes Details
Forecast Period 2023 to 2033
Historical Data Available for 2018 to 2022
Market Analysis US$ billion for Value
Key Countries Covered United States, United Kingdom, Japan, India, China, Australia, Germany
Key Segments Covered
  • Type
  • Application
  • Installation
  • Region
Key Companies Profiled
  • Pfizer Inc.
  • Abbott Laboratories
  • Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
  • Novartis AG
  • Bayer AG
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche AG,
  • Boehringer Ingelheim International GmbH
  • Bausch Health Companies Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals
  • AbbVie Inc. (Allergan plc)
  • Purdue Pharmaceuticals L.P.
  • Sun Pharmaceutical Industries Ltd.
  • Mallinckrodt Pharmaceuticals
  • Endo Pharmaceuticals Inc. [Endo International plc]
  • Assertio Therapeutics, Inc. [Assertio Holdings, Inc.]
Report Coverage Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing Available upon Request

Opioid Analgesics Market by Segmentation

By Drug Class:

  • Morphine
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Tramadol
  • Oxycodone
  • Dextromethorphan
  • Buprenorphine
  • Others

By Indication:

  • Surgical Pain
  • Cancer Pain
  • Neuropathic Pain
  • Other

By Route of Administration:

  • Oral
  • Parenteral
  • Transdermal
  • Other

By End User:

  • Hospitals
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East & Africa (MEA)

Frequently Asked Questions

What is the market value in 2023?

The market in 2023 is valued at US$ 43.3 billion.

What is the market share of Hospital pharmacies segment?

Hospital pharmacies are expected to account for a market share of 33.4%.

What is the likely CAGR until 2033?

The market will register a 5.2% CAGR until 2033.

What will be the market value in 2033?

By 2033, the market will reach US$ 72.0 billion.

What is the China’s CAGR of this market through 2033?

The Chinese market is likely to register a CAGR of 7.7% through 2033.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Morphine

        5.3.2. Codeine

        5.3.3. Fentanyl

        5.3.4. Meperidine

        5.3.5. Methadone

        5.3.6. Tramadol

        5.3.7. Oxycodone

        5.3.8. Dextromethorphan

        5.3.9. Buprenorphine

        5.3.10. Others

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

        6.3.1. Surgical Pain

        6.3.2. Cancer Pain

        6.3.3. Neuropathic Pain

        6.3.4. Other

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Administration 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Administration, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Administration, 2023 to 2033

        7.3.1. Oral

        7.3.2. Parenteral

        7.3.3. Transdermal

        7.3.4. Other

    7.4. Y-o-Y Growth Trend Analysis By Administration, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Administration, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        8.3.1. Hospitals

        8.3.2. Retail Pharmacies

        8.3.3. Drug Stores

        8.3.4. Online Pharmacies

    8.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Western Europe

        9.3.4. Eastern Europe

        9.3.5. South Asia and Pacific

        9.3.6. East Asia

        9.3.7. Middle East and Africa

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. U.S.

            10.2.1.2. Canada

        10.2.2. By Drug Class

        10.2.3. By Indication

        10.2.4. By Administration

        10.2.5. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Indication

        10.3.4. By Administration

        10.3.5. By End User

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Drug Class

        11.2.3. By Indication

        11.2.4. By Administration

        11.2.5. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Indication

        11.3.4. By Administration

        11.3.5. By End User

    11.4. Key Takeaways

12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. U.K.

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Western Europe

        12.2.2. By Drug Class

        12.2.3. By Indication

        12.2.4. By Administration

        12.2.5. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Indication

        12.3.4. By Administration

        12.3.5. By End User

    12.4. Key Takeaways

13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Poland

            13.2.1.2. Russia

            13.2.1.3. Czech Republic

            13.2.1.4. Romania

            13.2.1.5. Rest of Eastern Europe

        13.2.2. By Drug Class

        13.2.3. By Indication

        13.2.4. By Administration

        13.2.5. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Indication

        13.3.4. By Administration

        13.3.5. By End User

    13.4. Key Takeaways

14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. India

            14.2.1.2. Bangladesh

            14.2.1.3. Australia

            14.2.1.4. New Zealand

            14.2.1.5. Rest of South Asia and Pacific

        14.2.2. By Drug Class

        14.2.3. By Indication

        14.2.4. By Administration

        14.2.5. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Indication

        14.3.4. By Administration

        14.3.5. By End User

    14.4. Key Takeaways

15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. China

            15.2.1.2. Japan

            15.2.1.3. South Korea

        15.2.2. By Drug Class

        15.2.3. By Indication

        15.2.4. By Administration

        15.2.5. By End User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class

        15.3.3. By Indication

        15.3.4. By Administration

        15.3.5. By End User

    15.4. Key Takeaways

16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Drug Class

        16.2.3. By Indication

        16.2.4. By Administration

        16.2.5. By End User

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Drug Class

        16.3.3. By Indication

        16.3.4. By Administration

        16.3.5. By End User

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. U.S.

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Drug Class

            17.1.2.2. By Indication

            17.1.2.3. By Administration

            17.1.2.4. By End User

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Drug Class

            17.2.2.2. By Indication

            17.2.2.3. By Administration

            17.2.2.4. By End User

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Drug Class

            17.3.2.2. By Indication

            17.3.2.3. By Administration

            17.3.2.4. By End User

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Drug Class

            17.4.2.2. By Indication

            17.4.2.3. By Administration

            17.4.2.4. By End User

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Drug Class

            17.5.2.2. By Indication

            17.5.2.3. By Administration

            17.5.2.4. By End User

    17.6. U.K.

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Drug Class

            17.6.2.2. By Indication

            17.6.2.3. By Administration

            17.6.2.4. By End User

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Drug Class

            17.7.2.2. By Indication

            17.7.2.3. By Administration

            17.7.2.4. By End User

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Drug Class

            17.8.2.2. By Indication

            17.8.2.3. By Administration

            17.8.2.4. By End User

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Drug Class

            17.9.2.2. By Indication

            17.9.2.3. By Administration

            17.9.2.4. By End User

    17.10. Poland

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Drug Class

            17.10.2.2. By Indication

            17.10.2.3. By Administration

            17.10.2.4. By End User

    17.11. Russia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Drug Class

            17.11.2.2. By Indication

            17.11.2.3. By Administration

            17.11.2.4. By End User

    17.12. Czech Republic

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Drug Class

            17.12.2.2. By Indication

            17.12.2.3. By Administration

            17.12.2.4. By End User

    17.13. Romania

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Drug Class

            17.13.2.2. By Indication

            17.13.2.3. By Administration

            17.13.2.4. By End User

    17.14. India

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Drug Class

            17.14.2.2. By Indication

            17.14.2.3. By Administration

            17.14.2.4. By End User

    17.15. Bangladesh

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Drug Class

            17.15.2.2. By Indication

            17.15.2.3. By Administration

            17.15.2.4. By End User

    17.16. Australia

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Drug Class

            17.16.2.2. By Indication

            17.16.2.3. By Administration

            17.16.2.4. By End User

    17.17. New Zealand

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Drug Class

            17.17.2.2. By Indication

            17.17.2.3. By Administration

            17.17.2.4. By End User

    17.18. China

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Drug Class

            17.18.2.2. By Indication

            17.18.2.3. By Administration

            17.18.2.4. By End User

    17.19. Japan

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Drug Class

            17.19.2.2. By Indication

            17.19.2.3. By Administration

            17.19.2.4. By End User

    17.20. South Korea

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Drug Class

            17.20.2.2. By Indication

            17.20.2.3. By Administration

            17.20.2.4. By End User

    17.21. GCC Countries

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Drug Class

            17.21.2.2. By Indication

            17.21.2.3. By Administration

            17.21.2.4. By End User

    17.22. South Africa

        17.22.1. Pricing Analysis

        17.22.2. Market Share Analysis, 2022

            17.22.2.1. By Drug Class

            17.22.2.2. By Indication

            17.22.2.3. By Administration

            17.22.2.4. By End User

    17.23. Israel

        17.23.1. Pricing Analysis

        17.23.2. Market Share Analysis, 2022

            17.23.2.1. By Drug Class

            17.23.2.2. By Indication

            17.23.2.3. By Administration

            17.23.2.4. By End User

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Drug Class

        18.3.3. By Indication

        18.3.4. By Administration

        18.3.5. By End User

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Pfizer Inc.

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Abbott Laboratories

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Janssen Pharmaceuticals, Inc. [Johnson & Johnson]

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. Novartis AG

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Bayer AG

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. GlaxoSmithKline plc

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. F. Hoffmann-La Roche AG,

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. Boehringer Ingelheim International GmbH

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Bausch Health Companies Inc.

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. Sanofi S.A.

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Administration, 2018 to 2033

Table 5: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 9: North America Market Value (US$ Million) Forecast by Administration, 2018 to 2033

Table 10: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 13: Latin America Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 14: Latin America Market Value (US$ Million) Forecast by Administration, 2018 to 2033

Table 15: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 16: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: Western Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 18: Western Europe Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 19: Western Europe Market Value (US$ Million) Forecast by Administration, 2018 to 2033

Table 20: Western Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 21: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: Eastern Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 23: Eastern Europe Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 24: Eastern Europe Market Value (US$ Million) Forecast by Administration, 2018 to 2033

Table 25: Eastern Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 26: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 27: South Asia and Pacific Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 28: South Asia and Pacific Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 29: South Asia and Pacific Market Value (US$ Million) Forecast by Administration, 2018 to 2033

Table 30: South Asia and Pacific Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 31: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 32: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 33: East Asia Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 34: East Asia Market Value (US$ Million) Forecast by Administration, 2018 to 2033

Table 35: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033

Table 36: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 37: Middle East and Africa Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 38: Middle East and Africa Market Value (US$ Million) Forecast by Indication, 2018 to 2033

Table 39: Middle East and Africa Market Value (US$ Million) Forecast by Administration, 2018 to 2033

Table 40: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Indication, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Administration, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by End User, 2023 to 2033

Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 9: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 12: Global Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 13: Global Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 14: Global Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 15: Global Market Value (US$ Million) Analysis by Administration, 2018 to 2033

Figure 16: Global Market Value Share (%) and BPS Analysis by Administration, 2023 to 2033

Figure 17: Global Market Y-o-Y Growth (%) Projections by Administration, 2023 to 2033

Figure 18: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 19: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 20: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 21: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 22: Global Market Attractiveness by Indication, 2023 to 2033

Figure 23: Global Market Attractiveness by Administration, 2023 to 2033

Figure 24: Global Market Attractiveness by End User, 2023 to 2033

Figure 25: Global Market Attractiveness by Region, 2023 to 2033

Figure 26: North America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 27: North America Market Value (US$ Million) by Indication, 2023 to 2033

Figure 28: North America Market Value (US$ Million) by Administration, 2023 to 2033

Figure 29: North America Market Value (US$ Million) by End User, 2023 to 2033

Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 37: North America Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 38: North America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 39: North America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 40: North America Market Value (US$ Million) Analysis by Administration, 2018 to 2033

Figure 41: North America Market Value Share (%) and BPS Analysis by Administration, 2023 to 2033

Figure 42: North America Market Y-o-Y Growth (%) Projections by Administration, 2023 to 2033

Figure 43: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 44: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 45: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 46: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 47: North America Market Attractiveness by Indication, 2023 to 2033

Figure 48: North America Market Attractiveness by Administration, 2023 to 2033

Figure 49: North America Market Attractiveness by End User, 2023 to 2033

Figure 50: North America Market Attractiveness by Country, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 52: Latin America Market Value (US$ Million) by Indication, 2023 to 2033

Figure 53: Latin America Market Value (US$ Million) by Administration, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) by End User, 2023 to 2033

Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 59: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 62: Latin America Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 63: Latin America Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 65: Latin America Market Value (US$ Million) Analysis by Administration, 2018 to 2033

Figure 66: Latin America Market Value Share (%) and BPS Analysis by Administration, 2023 to 2033

Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Administration, 2023 to 2033

Figure 68: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 69: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 70: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 71: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 72: Latin America Market Attractiveness by Indication, 2023 to 2033

Figure 73: Latin America Market Attractiveness by Administration, 2023 to 2033

Figure 74: Latin America Market Attractiveness by End User, 2023 to 2033

Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 76: Western Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 77: Western Europe Market Value (US$ Million) by Indication, 2023 to 2033

Figure 78: Western Europe Market Value (US$ Million) by Administration, 2023 to 2033

Figure 79: Western Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 80: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 81: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 82: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 83: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 84: Western Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 85: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 86: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 87: Western Europe Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 88: Western Europe Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 89: Western Europe Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 90: Western Europe Market Value (US$ Million) Analysis by Administration, 2018 to 2033

Figure 91: Western Europe Market Value Share (%) and BPS Analysis by Administration, 2023 to 2033

Figure 92: Western Europe Market Y-o-Y Growth (%) Projections by Administration, 2023 to 2033

Figure 93: Western Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 94: Western Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 95: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 96: Western Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 97: Western Europe Market Attractiveness by Indication, 2023 to 2033

Figure 98: Western Europe Market Attractiveness by Administration, 2023 to 2033

Figure 99: Western Europe Market Attractiveness by End User, 2023 to 2033

Figure 100: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 101: Eastern Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 102: Eastern Europe Market Value (US$ Million) by Indication, 2023 to 2033

Figure 103: Eastern Europe Market Value (US$ Million) by Administration, 2023 to 2033

Figure 104: Eastern Europe Market Value (US$ Million) by End User, 2023 to 2033

Figure 105: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 106: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 107: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 108: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 109: Eastern Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 110: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 111: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 112: Eastern Europe Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 113: Eastern Europe Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 114: Eastern Europe Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 115: Eastern Europe Market Value (US$ Million) Analysis by Administration, 2018 to 2033

Figure 116: Eastern Europe Market Value Share (%) and BPS Analysis by Administration, 2023 to 2033

Figure 117: Eastern Europe Market Y-o-Y Growth (%) Projections by Administration, 2023 to 2033

Figure 118: Eastern Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 119: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 120: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 121: Eastern Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 122: Eastern Europe Market Attractiveness by Indication, 2023 to 2033

Figure 123: Eastern Europe Market Attractiveness by Administration, 2023 to 2033

Figure 124: Eastern Europe Market Attractiveness by End User, 2023 to 2033

Figure 125: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 126: South Asia and Pacific Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 127: South Asia and Pacific Market Value (US$ Million) by Indication, 2023 to 2033

Figure 128: South Asia and Pacific Market Value (US$ Million) by Administration, 2023 to 2033

Figure 129: South Asia and Pacific Market Value (US$ Million) by End User, 2023 to 2033

Figure 130: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 131: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 132: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 133: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 134: South Asia and Pacific Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 135: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 136: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 137: South Asia and Pacific Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 138: South Asia and Pacific Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 139: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 140: South Asia and Pacific Market Value (US$ Million) Analysis by Administration, 2018 to 2033

Figure 141: South Asia and Pacific Market Value Share (%) and BPS Analysis by Administration, 2023 to 2033

Figure 142: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Administration, 2023 to 2033

Figure 143: South Asia and Pacific Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 144: South Asia and Pacific Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 145: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 146: South Asia and Pacific Market Attractiveness by Drug Class, 2023 to 2033

Figure 147: South Asia and Pacific Market Attractiveness by Indication, 2023 to 2033

Figure 148: South Asia and Pacific Market Attractiveness by Administration, 2023 to 2033

Figure 149: South Asia and Pacific Market Attractiveness by End User, 2023 to 2033

Figure 150: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033

Figure 151: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 152: East Asia Market Value (US$ Million) by Indication, 2023 to 2033

Figure 153: East Asia Market Value (US$ Million) by Administration, 2023 to 2033

Figure 154: East Asia Market Value (US$ Million) by End User, 2023 to 2033

Figure 155: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 156: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 157: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 158: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 159: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 160: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 161: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 162: East Asia Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 163: East Asia Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 164: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 165: East Asia Market Value (US$ Million) Analysis by Administration, 2018 to 2033

Figure 166: East Asia Market Value Share (%) and BPS Analysis by Administration, 2023 to 2033

Figure 167: East Asia Market Y-o-Y Growth (%) Projections by Administration, 2023 to 2033

Figure 168: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 169: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 170: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 171: East Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 172: East Asia Market Attractiveness by Indication, 2023 to 2033

Figure 173: East Asia Market Attractiveness by Administration, 2023 to 2033

Figure 174: East Asia Market Attractiveness by End User, 2023 to 2033

Figure 175: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 176: Middle East and Africa Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 177: Middle East and Africa Market Value (US$ Million) by Indication, 2023 to 2033

Figure 178: Middle East and Africa Market Value (US$ Million) by Administration, 2023 to 2033

Figure 179: Middle East and Africa Market Value (US$ Million) by End User, 2023 to 2033

Figure 180: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 181: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 182: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 183: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 184: Middle East and Africa Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 185: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 186: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 187: Middle East and Africa Market Value (US$ Million) Analysis by Indication, 2018 to 2033

Figure 188: Middle East and Africa Market Value Share (%) and BPS Analysis by Indication, 2023 to 2033

Figure 189: Middle East and Africa Market Y-o-Y Growth (%) Projections by Indication, 2023 to 2033

Figure 190: Middle East and Africa Market Value (US$ Million) Analysis by Administration, 2018 to 2033

Figure 191: Middle East and Africa Market Value Share (%) and BPS Analysis by Administration, 2023 to 2033

Figure 192: Middle East and Africa Market Y-o-Y Growth (%) Projections by Administration, 2023 to 2033

Figure 193: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2018 to 2033

Figure 194: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2023 to 2033

Figure 195: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033

Figure 196: Middle East and Africa Market Attractiveness by Drug Class, 2023 to 2033

Figure 197: Middle East and Africa Market Attractiveness by Indication, 2023 to 2033

Figure 198: Middle East and Africa Market Attractiveness by Administration, 2023 to 2033

Figure 199: Middle East and Africa Market Attractiveness by End User, 2023 to 2033

Figure 200: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Palliative Care Market

Published : October 2022

Healthcare

Pain Management Devices Market

Published : October 2022

Explore Healthcare Insights

View Reports